1098 related articles for article (PubMed ID: 28139422)
1. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
2. Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy.
Rutenberg MS; Meister M; Amin PP; Hussain A; Naslund MJ; Kwok Y
Brachytherapy; 2016; 15(6):722-729. PubMed ID: 27693225
[TBL] [Abstract][Full Text] [Related]
3. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
5. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112
[TBL] [Abstract][Full Text] [Related]
6. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
7. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS
Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.
Lee B; Shinohara K; Weinberg V; Gottschalk AR; Pouliot J; Roach M; Hsu IC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1106-12. PubMed ID: 17197119
[TBL] [Abstract][Full Text] [Related]
9. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
10. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
11. Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium.
Ishiyama H; Kamitani N; Kawamura H; Kato S; Aoki M; Kariya S; Matsumura T; Kaidu M; Yoshida K; Hashimoto Y; Noda Y; Lim KHC; Kawase T; Takahashi T; Inaba K; Kumano M; Yoshikawa N; Yoshioka Y; Nakamura K; Hiratsuka J; Itami J; Hayakawa K
Brachytherapy; 2017; 16(3):503-510. PubMed ID: 28222973
[TBL] [Abstract][Full Text] [Related]
12. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
13. Does prostate-specific antigen nadir predict longer-term outcomes of prostate cancer after neoadjuvant and adjuvant androgen deprivation therapy in conjunction with brachytherapy?
Morris LM; Izard MA; Wan WY
Brachytherapy; 2015; 14(3):322-8. PubMed ID: 25487524
[TBL] [Abstract][Full Text] [Related]
14. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.
Martínez-Monge R; Moreno M; Ciérvide R; Cambeiro M; Pérez-Gracia JL; Gil-Bazo I; Gaztañaga M; Arbea L; Pascual I; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e469-76. PubMed ID: 22284039
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).
Crook JM; Zhang P; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Pervez N; Vigneault E; Catton C; Michalski J; Roach M; Beyer D; Jani A; Horwitz E; Donavanik V; Sandler H
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):335-343. PubMed ID: 30312717
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
17. External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer.
Strom TJ; Hutchinson SZ; Shrinath K; Cruz AA; Figura NB; Nethers K; Biagioli MC; Fernandez DC; Heysek RV; Wilder RB
Int Braz J Urol; 2014; 40(4):474-83. PubMed ID: 25251952
[TBL] [Abstract][Full Text] [Related]
18. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
19. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation.
Wong WW; Buskirk SJ; Schild SE; Prussak KA; Davis BJ
J Urol; 2006 Nov; 176(5):2020-4. PubMed ID: 17070243
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy.
Aizawa R; Takayama K; Nakamura K; Inoue T; Yamasaki T; Kobayashi T; Akamatsu S; Ogawa O; Mizowaki T
Int J Clin Oncol; 2020 Apr; 25(4):713-719. PubMed ID: 31820209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
